Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA
Clinical trial NCT03544099 · TERMINATED
Trial details
- NCT number
- NCT03544099
- Sponsor
- National Health Research Institutes, Taiwan
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-07
- Primary completion
- 2021-12-31
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.